Table 3.

Positivity for gonorrhoea, Chlamydia, syphilis and HIV among men who have sex with men attending a sexual health centre in Melbourne, 2011–2018, stratified by men who have sex with men only (MSMO) and men who have sex with men and women (MSMW)

HIV/STI	Men who have sex with men only (N=12 795)			Men who have sex with men and women (N=1979)			P value
	No of men tested, N	No of positive, n	Positivity, % (95% CI)	No of men tested, N	No of positive, n	Positivity, % (95% CI)
Gonorrhoea
Oropharyngeal	11 810	682	5.8 (5.4 to 6.2)	1711	68	4.0 (3.1 to 5.0)	0.002
Urethral*	11 699	390	3.3 (3.0 to 3.7)	1885	52	2.8 (2.1 to 3.6)	0.192
Anorectal	11 080	745	6.7 (6.3 to 7.2)	1404	58	4.1 (3.2 to 5.3)	<0.001
Any anatomical site†	11 951	1321	11.1 (10.5 to 11.6)	1829	140	7.7 (6.5 to 9.0)	<0.001
Chlamydia
Urethral	11 699	410	3.5 (3.2 to 3.9)	1885	73	3.9 (3.0 to 4.8)	0.423
Anorectal	11 043	989	9.0 (8.4 to 9.5)	1404	83	5.9 (4.7 to 7.3)	<0.001
Any anatomical site†	11 891	1272	10.7 (10.1 to 11.3)	1907	141	7.4 (6.3 to 8.7)	<0.001
Syphilis	11 317	797	7.0 (6.6 to 7.5)	1773	81	4.6 (3.6 to 5.6)	<0.001
HIV
New diagnosis‡	11 102	262	2.4 (2.1 to 2.7)	1774	10	0.6 (0.3 to 1.0)	<0.001
Previous diagnosis	12 795	316	2.5 (2.2 to 2.8)	1979	7	0.4 (0.1 to 0.7)	<0.001

*Before 2015, urethral gonorrhoea testing was only performed among symptomatic MSM with urethral symptoms or self-reported as contact of infection. The number of people tested corresponds to the number of people tested for urethral chlamydia.

†Any anatomical site for gonorrhoea includes urethral, anorectal and oropharyngeal; while any site for chlamydia includes urethral and anorectal.

‡Only including HIV cases diagnosed on the day of the first visit.

CI, confidence interval; STI, sexually transmitted infection.